Concepedia

Author

Bruno Bockorny

Beth Israel Deaconess Medical CenterORCID

Also Known As

B Bockorny, B. Bockorny, Bruno B. Bockorny, Bruno Bockorny

190

Publications

2.1K

Citations

18

H-Index

60

Concepts

All Affiliations

Beth Israel Deaconess Medical CenterHarvard UniversityHonorHealthDana-Farber Cancer InstituteAgenus (United States)
BB

About

Bruno Bockorny is an author at Beth Israel Deaconess Medical Center specializing in medicine, oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

11

764

2

Public Health

2

2

48

3

Engineering

1

1

47

4

Cell Biology

1

1

47

5

Cellular Therapies

1

1

54

Bruno Bockorny

×

23

Publications

1.5K

Citations

15

H-Index

YearCitations

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Bruno Bockorny, Valerya Semenisty, Teresa Macarulla,

Nature Medicine

2020

501

Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression

Maria Rusan, Kapsok Li, Yvonne Li,

Cancer Discovery

2017

140

PDX-derived organoids model in vivo drug response and secrete biomarkers

Ling Huang, Bruno Bockorny, Indranil Paul,

JCI Insight

2020

125

OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models

Myriam Fabre, Cristina Suárez Ferrer, Saioa Domínguez-Hormaetxe,

Clinical Cancer Research

2020

92

Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

Andrea J. Bullock, Benjamin L. Schlechter, Marwan Fakih,

Nature Medicine

2024

79

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

Bruno Bockorny, Teresa Macarulla, Valerya Semenisty,

Clinical Cancer Research

2021

78

Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score

Brandon Webb, Kristin Dascomb, Edward Stenehjem,

Antimicrobial Agents and Chemotherapy

2016

75

RAS–MAPK Reactivation Facilitates Acquired Resistance in <i>FGFR1</i> -Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade

Bruno Bockorny, Maria Rusan, Wankun Chen,

Molecular Cancer Therapeutics

2018

60

Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).

Anthony B. El-Khoueiry, Marwan Fakih, Michael S. Gordon,

Journal of Clinical Oncology

2023

54

Exploiting pancreatic cancer metabolism: challenges and opportunities

Maria Chiara De Santis, Bruno Bockorny, Emilio Hirsch,

Trends in Molecular Medicine

2024

50

Page 1